SCHEMBL14937486

SCHEMBL14937486

Cn1nccc1C(=O)NNC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 3/20 0.51
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.46
MAPT P10636 1/20 0.46
OXTR P30559 1/20 0.46
AVPR1A P37288 1/20 0.46
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 2/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
NAMPT P43490 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937993 0.83 NPC1 (0.68) KMT2AMAPTNPC1CYP1A2CYP2D6
SCHEMBL14938017 0.78 OXTR (0.57) KMT2AOXTRAVPR1ASMN1; SMN2
SCHEMBL24071247 0.75 KMT2A (0.57) KMT2AL3MBTL1NPC1CYP1A2CYP2D6
SCHEMBL14938206 0.72 ATM (0.42) KMT2AL3MBTL1ATMOXTRAVPR1A
SCHEMBL14527340 0.72 KIF11 (0.66) TLR7POLBL3MBTL1ALDH1A1
SCHEMBL12110034 0.71 KMT2A (0.60) KMT2AL3MBTL1NPC1CYP1A2CYP2D6
SCHEMBL29492368 0.71 ALDH1A1 (0.50) KMT2AL3MBTL1MAPTNPC1CYP1A2
SCHEMBL3432317 0.71 KMT2A (0.60) KMT2AL3MBTL1NPC1CYP1A2CYP2D6
SCHEMBL14937546 0.70 GPBAR1 (0.46) OXTRAVPR1ANPC1RAB9A
SCHEMBL22302816 0.70 KMT2A (0.55) POLBKMT2AL3MBTL1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A TLR7 2734/4885POLB 3540/4885KMT2A 2879/4885
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 TLR7 4337/4885POLB 3099/4885KMT2A 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.